Key result
Mortality for lung cancer patients with secondary pulmonary hypertension rises ~6% annually over two decades.
Why the study?
Despite recognition of cancer-associated pulmonary hypertension, its epidemiology in lung cancer is poorly characterized.
Cohort (n=8,428)
Yes
Mortality associated with secondary pulmonary hypertension among lung cancer patients has increased three-fold over the past two decades in the US, highlighting it as an under-recognized contributor to morbidity.
Answers are grounded in this paper and cite their sources.
Mortality from secondary pulmonary hypertension in lung cancer has risen markedly; observational data leave open whether screening or therapies alter outcomes.
e20775 Background: Lung cancer remains a leading cause of cancer-related mortality globally. In advanced stages, tumor-driven vascular remodeling can predispose patients to secondary Pulmonary Hypertension (PH), contributing to significant cardiopulmonary morbidity. Despite recognition of cancer-associated PH, its epidemiology in lung cancer is poorly characterized. Methods: In this retrospective cohort study, we analyzed mortality records from the CDC WONDER database (2003–2023) for decedents aged ≥45 years with both lung cancer (ICD-10: C34) and secondary PH (ICD-10: I27.2) listed as contributing or underlying causes of death. Analyses adhered to STROBE guidelines for observational studies. Age-adjusted mortality rates (AAMRs) per 100,000 population, annual percent changes (APCs), and average annual percent changes (AAPCs) were estimated using Joinpoint regression, stratified by age, sex, US census region, urbanization, state, and place of death. Results: We identified 8,428 deaths over 21 years. Overall AAMR increased from 0.15 in 2003 to 0.52 per 100,000 in 2023 (AAPC 6.31%, 95% CI 5.54–7.09). Adults aged ≥65 years experienced the largest increases, with a rapid rise from 2003–2011 (APC 10.08%, 95% CI 7.82–12.37), plateau 2011–2014, and further increase 2014–2023 (APC 8.07%, 95% CI 6.89–9.24; AAPC 7.15%, 95% CI 4.81–9.52). Males exhibited consistently higher AAMRs than females (AAPC 6.66%, 95% CI 3.68–9.74). Regional variation was notable, with the West showing the highest AAPC (8.12%, 95% CI 7.32–8.92), followed by Midwest, South, and Northeast. Mortality increased significantly in metropolitan areas from 2003–2020 (APC 5.87%, 95% CI 4.84–6.91) and in non-metropolitan areas after 2005 (APC 6.41%, 95% CI 5.06–7.78). Most deaths occurred in inpatient facilities (3,431), followed by home (2,846). States with the greatest mortality burden included California, Florida, Texas, Ohio, Pennsylvania, and Colorado. Conclusions: A three-fold rise in AAMR over two decades highlights secondary PH as an under-recognized contributor to morbidity among lung cancer patients, particularly older males in Western metropolitan regions. These findings underscore the need for enhanced screening, early recognition, and further research into tumor-mediated mechanisms driving PH in lung cancer.
No takes yet. Share an insight, caveat, or question.
Mansoor et al. (2026) conducted a cohort in Lung cancer and secondary Pulmonary Hypertension (n=8,428). Age-adjusted mortality rates for lung cancer patients with secondary pulmonary hypertension increased from 0.15 to 0.52 per 100,000 between 2003 and 2023.
Synapse has enriched 10 related papers. Consider them for comparative context: